Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06740240 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer

StatusRecruiting
PhaseEarly Phase 1
Started2024-03-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 18, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Trial Details
NCT Number NCT06740240
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Tumor
Enrollment 30 participants
Start Date 2024-03-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-18